

R&D Pipeline

(As of May 20, 2025)



Code Generic name (Product name)	Indication	Preclinical	Clinical Trial	Application	Approval	Mechanism
JR-141 pabinafusp alfa (IZCARGO® for I.V. infusion 10mg)	MPS type II (Hunter)	Japan				BBB-penetrating iduronate-2-sulfatase (rDNA origin)
		Global Ph3				
JR-171 lepunafusp alfa	MPS type I (Hurler etc.)	Global Ph1/2				BBB-penetrating α-L-iduronidase (rDNA origin)
JR-142 redalsomatropin alfa	Pediatric growth hormone deficiency	Japan Ph3				Long-acting human growth hormone (rDNA origin)
JR-441	MPS type III A (Sanfilippo A)	Germany Ph1/2				BBB-penetrating heparan N-sulfatase (rDNA origin)
		Japan Ph1				
JR-446	MPS type III B (Sanfilippo B)	Japan Ph1/2				BBB-penetrating α-N-acetylglucosaminidase (rDNA origin) Partnering with MEDIPAL HOLDINGS
JR-471	Fucosidosis					BBB-penetrating α-L-fucosidase (rDNA origin) Partnering with MEDIPAL HOLDINGS

※Only high-priority projects in the clinical stage or soon to be in the clinical stage are listed in the above table.